Parexel Gets Boost From Small-Firm Contracts
This article was originally published in The Pink Sheet Daily
Executive Summary
Parexel experiences an increased level of business from smaller divisions or standalone companies that are "embracing a more strategic way of outsourcing," CEO Rickenbach said. The contract research organization also saw an increase in later stage trials, including "healthy" demand for Phase IV studies.